Cargando…
Nivolumab-Induced Pneumonitis in a Patient With Urothelial Cancer
The introduction of immune checkpoint inhibitors has revolutionized cancer treatment. These drugs function by inhibiting the binding of programmed death-1 (PD-1) and its ligand, PD-L1, which inhibits the immune response against cancer cells. Nivolumab is a PD-1 inhibitor that specifically targets th...
Autores principales: | Kasi, Arbab Furquan Ud din, Nagi, Mohammad Imran, Kasi, Burhanuddin A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290746/ https://www.ncbi.nlm.nih.gov/pubmed/37366435 http://dx.doi.org/10.7759/cureus.39511 |
Ejemplares similares
-
A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment
por: Al-Saghir, Tala, et al.
Publicado: (2023) -
Dabbing-Induced Hypersensitivity Pneumonitis
por: Haddad, Ibrahim, et al.
Publicado: (2021) -
Nivolumab-Induced Isolated Neutropenia
por: Waqas, Aimal, et al.
Publicado: (2023) -
The prevalence, angiographic profile and clinical features, management, and outcomes of coronary artery perforation secondary to percutaneous coronary interventions in Pakistan: a retrospective cohort study
por: Khan, Aiman, et al.
Publicado: (2023) -
Paraneoplastic Necrotizing Myopathy Post Lumpectomy and Chemotherapy for Early Breast Cancer
por: Venkatesh, Priyanka, et al.
Publicado: (2020)